Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
作者信息
Yeon Jong Eun
机构信息
Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
出版信息
Clin Mol Hepatol. 2018 Sep;24(3):294-296. doi: 10.3350/cmh.2018.1009. Epub 2018 Sep 11.
Abstract
摘要
相似文献
1
Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?对于2型慢性丙型肝炎患者，传统的索磷布韦联合利巴韦林治疗方案对韩国人是否仍然有效？
Clin Mol Hepatol. 2018 Sep;24(3):294-296. doi: 10.3350/cmh.2018.1009. Epub 2018 Sep 11.
2
Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India.索非布韦联合利巴韦林用于印度初治的慢性丙型肝炎病毒1型或3型感染患者
J Viral Hepat. 2017 May;24(5):371-379. doi: 10.1111/jvh.12654. Epub 2016 Dec 9.
3
Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.对于以基因3型为主的慢性丙型肝炎患者，索磷布韦联合利巴韦林的双重治疗与聚乙二醇干扰素联合索磷布韦和利巴韦林的三联疗法效果相当。
J Gastroenterol Hepatol. 2017 Apr;32(4):859-863. doi: 10.1111/jgh.13595.
4
Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study.基于索磷布韦的疗法治疗慢性丙型肝炎基因3型：一项真实世界研究
Hepatol Int. 2017 May;11(3):277-285. doi: 10.1007/s12072-017-9794-1. Epub 2017 Mar 31.
5
Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.在合并感染HIV的慢性丙型肝炎患者中，达卡他韦与索磷布韦联合用药对比索磷布韦与利巴韦林联合用药：一项匹配调整间接比较研究
Clin Ther. 2016 Feb;38(2):404-12. doi: 10.1016/j.clinthera.2015.12.017. Epub 2016 Feb 3.
6
Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4.索磷布韦联合利巴韦林治疗埃及 4 型丙型肝炎患者。
J Hepatol. 2015 Sep;63(3):581-5. doi: 10.1016/j.jhep.2015.04.023. Epub 2015 May 1.
7
Does Ribavirin Still Have a Role in Sofosbuvir and Velpatasvir Therapy for Patients With HCV Genotype 3 Infection and Cirrhosis?对于丙型肝炎病毒3型感染并伴有肝硬化的患者，利巴韦林在索磷布韦和维帕他韦治疗中仍有作用吗？
Gastroenterology. 2018 Oct;155(4):969-971. doi: 10.1053/j.gastro.2018.09.003. Epub 2018 Sep 8.
8
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.索磷布韦/维帕他韦联合治疗方案治疗曾接受治疗的 1 型或 3 型丙型肝炎病毒感染患者：一项随机试验。
Ann Intern Med. 2015 Dec 1;163(11):809-17. doi: 10.7326/M15-1014. Epub 2015 Nov 10.
9
Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C.索磷布韦联合利巴韦林在社区治疗老年 2 型慢性丙型肝炎患者的有效性和安全性。
Dig Liver Dis. 2017 Sep;49(9):1029-1035. doi: 10.1016/j.dld.2017.04.012. Epub 2017 Apr 27.
10
Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities.索磷布韦联合利巴韦林治疗丙型肝炎病毒基因型 2 感染、代偿期肝硬化和多种合并症的退伍军人的疗效。
Clin Gastroenterol Hepatol. 2017 Feb;15(2):282-288. doi: 10.1016/j.cgh.2016.05.024. Epub 2016 May 27.
引用本文的文献
1
Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution.真实世界中在单家医疗机构接受格卡瑞韦哌仑他韦治疗的韩国慢性丙型肝炎患者的疗效和安全性。
Gut Liver. 2021 May 15;15(3):440-450. doi: 10.5009/gnl19393.
2
Critical View on the Usage of Ribavirin in Already Existing Psychostimulant-Use Disorder.对已存在的精神兴奋剂使用障碍中利巴韦林使用的批判性看法。
Curr Pharm Des. 2020;26(4):466-484. doi: 10.2174/1381612826666200115094642.
本文引用的文献
1
2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.2017年丙型肝炎管理的KASL临床实践指南：慢性丙型肝炎的治疗
Clin Mol Hepatol. 2018 Sep;24(3):169-229. doi: 10.3350/cmh.2018.1004. Epub 2018 Aug 10.
2
Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study.索磷布韦联合利巴韦林治疗韩国 2 型丙型肝炎病毒感染患者的疗效和安全性：一项回顾性多机构研究。
Clin Mol Hepatol. 2018 Sep;24(3):311-318. doi: 10.3350/cmh.2017.0070. Epub 2018 Jun 4.
3
EASL Recommendations on Treatment of Hepatitis C 2018.2018年欧洲肝脏研究学会丙型肝炎治疗推荐意见
J Hepatol. 2018 Aug;69(2):461-511. doi: 10.1016/j.jhep.2018.03.026. Epub 2018 Apr 9.
4
HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study.肝硬化患者直接作用抗病毒药物治疗后的 HCV 清除率：ITAL-C 网络研究。
Dig Liver Dis. 2017 Sep;49(9):1022-1028. doi: 10.1016/j.dld.2017.03.025. Epub 2017 Apr 8.
5
Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.索磷布韦联合利巴韦林治疗肝硬化合并基因 2 型 HCV 感染患者：真实世界经验。
J Hepatol. 2017 Apr;66(4):711-717. doi: 10.1016/j.jhep.2016.12.002. Epub 2016 Dec 10.
6
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.索磷布韦联合利巴韦林治疗丙型肝炎病毒2型感染的有效性和安全性：真实世界临床实践丙型肝炎病毒靶向研究结果
Gut. 2017 Oct;66(10):1844-1852. doi: 10.1136/gutjnl-2016-311609. Epub 2016 Jul 13.
7
A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus.一项针对初治和经治的慢性丙型肝炎病毒2型感染韩国患者的索磷布韦加利巴韦林3b期研究。
J Viral Hepat. 2016 May;23(5):358-65. doi: 10.1111/jvh.12499. Epub 2016 Feb 10.
8
A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection.索非布韦联合利巴韦林用于台湾慢性2型丙型肝炎病毒感染患者的3b期研究。
Liver Int. 2016 Aug;36(8):1101-7. doi: 10.1111/liv.13082. Epub 2016 Mar 23.
9
Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.索磷布韦联合利巴韦林加或不加聚乙二醇干扰素-α治疗丙型肝炎病毒基因型 3 感染且有肝硬化的经治患者和丙型肝炎病毒基因型 2 感染且有肝硬化的经治患者的疗效。
Gastroenterology. 2015 Nov;149(6):1462-70. doi: 10.1053/j.gastro.2015.07.043. Epub 2015 Aug 4.
10
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.丙型肝炎指南：美国肝病研究学会-美国感染病学会关于丙型肝炎病毒感染成人检测、管理及治疗的建议
Hepatology. 2015 Sep;62(3):932-54. doi: 10.1002/hep.27950. Epub 2015 Aug 4.
Zotero 插件